Syra Health Corp. Class A Common Stock (SYRA) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
SYRA's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
SYRA Revenue Analysis (2020–2024)
As of March 2, 2026, Syra Health Corp. Class A Common Stock (SYRA) generated trailing twelve-month (TTM) revenue of $7.5 million, reflecting significant decline in growth of -25.1% year-over-year. The most recent quarter (Q3 2025) recorded $1.7 million in revenue, down 13.3% sequentially.
Looking at the longer-term picture, SYRA's historical revenue data shows a 3-year CAGR of +78.2%. The company achieved its highest annual revenue of $8.0 million in 2024, representing a new all-time high.
Revenue diversification analysis shows SYRA's business is primarily driven by Population Health (100%). With over half of revenue concentrated in Population Health, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SOLV (+0.9% YoY), HCSG (+6.3% YoY), and AMN (-8.5% YoY), SYRA has underperformed the peer group in terms of revenue growth. Compare SYRA vs SOLV →
Peer Comparison
Compare SYRA's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SYRACurrent | $7M | -25.1% | - | -47.2% | |
| SOLV | $8.3B | +0.9% | - | 26.2% | |
| HCSG | $1.8B | +6.3% | +0.9% | 2.6% | |
| AMN | $3.0B | -8.5% | +6.1% | -3.4% | |
| CCRN | $1.3B | -22.1% | +10.3% | -1.3% | |
| CCEL | $32M | -0.3% | +0.1% | 10.9% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $8.0M | +44.7% | $1.7M | 20.7% | $-3,764,885 | -47.2% |
| 2023 | $5.5M | -1.8% | $1.4M | 25.5% | $-2,887,599 | -52.4% |
| 2022 | $5.6M | +298.4% | $1.1M | 18.9% | $-2,089,695 | -37.2% |
| 2021 | $1.4M | - | $430K | 30.5% | $-3,280 | -0.2% |
| 2020 | $0 | - | $0 | - | $-4,267 | - |
See SYRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYRA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SYRA vs AGIO
See how SYRA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SYRA's revenue growth accelerating or slowing?
SYRA revenue declined -25.1% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $7M. This reverses the prior growth trend.
What is SYRA's long-term revenue growth rate?
Syra Health Corp. Class A Common Stock's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -25.1% is below this long-term average.
How is SYRA's revenue distributed by segment?
SYRA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.